High BCR–ABL/GUSIS Levels at Diagnosis of Chronic Phase CML Are Associated with Unfavorable Responses to Standard-Dose Imatinib-Reference-Cited by-同舟云学术

High BCR–ABL/GUSIS Levels at Diagnosis of Chronic Phase CML Are Associated with Unfavorable Responses to Standard-Dose Imatinib

Published:2017-09-19 Issue:23 Volume:23 Page:7189-7198
ISSN:1078-0432
Container-title:Clinical Cancer Research
language:en
Short-container-title:Clin Cancer Res

Author:

Vigneri Paolo,Stagno Fabio,Stella Stefania,Cupri Alessandra,Forte Stefano,Massimino Michele,Antolino Agostino,Siragusa Sergio,Mannina Donato,Impera Stefana Stella,Musolino Caterina,Malato Alessandra,Mineo Giuseppe,Tomaselli Carmela,Murgano Pamela,Musso Maurizio,Morabito Fortunato,Molica Stefano,Martino Bruno,Manzella Livia,Müller Martin C.,Hochhaus Andreas,Raimondo Francesco Di

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 31 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Continuous therapy response references for BCR::ABL1 monitoring in pediatric chronic myeloid leukemia;Scientific Reports;2023-10-24

2. High BCR::ABL1 Expression Defines CD34+ Cells with Significant Alterations in Signal Transduction, Short-Proliferative Potential and Self-Renewal Ability;OncoTargets and Therapy;2023-10

3. Analysis of factors predicting the efficacy of Imatinib in patients with Chronic Myeloid Leukemia: A retrospective analysis;Medical Science and Discovery;2022-09-23

4. Impact of Different Cell Counting Methods in Molecular Monitoring of Chronic Myeloid Leukemia Patients;Diagnostics;2022-04-22

5. Combined Inhibition of Bcl2 and Bcr-Abl1 Exercises Anti-Leukemia Activity but Does Not Eradicate the Primitive Leukemic Cells;Journal of Clinical Medicine;2021-11-29